
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.aa42804411e1.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.6c8346f5860b.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3b12438b8d66.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.6539a0a78536cfdc1fa6.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs2.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-pnas.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.e622fd8870cb011febf1.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>MEK1 mutations confer resistance to MEK and B-RAF inhibition - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD4345D0130BF5000036921C02C12E.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="1.5.0.post1+55721b3" />

<meta name="ncbi_domain" content="pnas" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC2777185/" />


    


        <script>
            
            var useOfficialGovtHeader = true;
        </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777185/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Proceedings of the National Academy of Sciences of the United States of America" /><meta name="citation_title" content="MEK1 mutations confer resistance to MEK and B-RAF inhibition" /><meta name="citation_author" content="Caroline M. Emery" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Krishna G. Vijayendran" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Marie C. Zipser" /><meta name="citation_author_institution" content="cDepartment of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland;" /><meta name="citation_author" content="Allison M. Sawyer" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Lili Niu" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Jessica J. Kim" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Charles Hatton" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Rajiv Chopra" /><meta name="citation_author_institution" content="dNovartis Institute of BioMedical Research, Cambridge, MA 02139;" /><meta name="citation_author" content="Patrick A. Oberholzer" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author_institution" content="cDepartment of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland;" /><meta name="citation_author_institution" content="eThe Broad Institute, Cambridge, MA 02142; and" /><meta name="citation_author" content="Maria B. Karpova" /><meta name="citation_author_institution" content="cDepartment of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland;" /><meta name="citation_author" content="Laura E. MacConaill" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author" content="Jianming Zhang" /><meta name="citation_author_institution" content="fDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115" /><meta name="citation_author" content="Nathanael S. Gray" /><meta name="citation_author_institution" content="fDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115" /><meta name="citation_author" content="William R. Sellers" /><meta name="citation_author_institution" content="dNovartis Institute of BioMedical Research, Cambridge, MA 02139;" /><meta name="citation_author" content="Reinhard Dummer" /><meta name="citation_author_institution" content="cDepartment of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland;" /><meta name="citation_author" content="Levi A. Garraway" /><meta name="citation_author_institution" content="aDepartment of Medical Oncology and" /><meta name="citation_author_institution" content="bCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;" /><meta name="citation_author_institution" content="eThe Broad Institute, Cambridge, MA 02142; and" /><meta name="citation_publication_date" content="2009/12/12" /><meta name="citation_issue" content="48" /><meta name="citation_volume" content="106" /><meta name="citation_firstpage" content="20411" /><meta name="citation_doi" content="10.1073/pnas.0905833106" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2777185/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC2777185/" /><meta name="citation_pmid" content="19915144" /><meta name="DC.Title" content="MEK1 mutations confer resistance to MEK and B-RAF inhibition" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Academy of Sciences" /><meta name="DC.Contributor" content="Caroline M. Emery" /><meta name="DC.Contributor" content="Krishna G. Vijayendran" /><meta name="DC.Contributor" content="Marie C. Zipser" /><meta name="DC.Contributor" content="Allison M. Sawyer" /><meta name="DC.Contributor" content="Lili Niu" /><meta name="DC.Contributor" content="Jessica J. Kim" /><meta name="DC.Contributor" content="Charles Hatton" /><meta name="DC.Contributor" content="Rajiv Chopra" /><meta name="DC.Contributor" content="Patrick A. Oberholzer" /><meta name="DC.Contributor" content="Maria B. Karpova" /><meta name="DC.Contributor" content="Laura E. MacConaill" /><meta name="DC.Contributor" content="Jianming Zhang" /><meta name="DC.Contributor" content="Nathanael S. Gray" /><meta name="DC.Contributor" content="William R. Sellers" /><meta name="DC.Contributor" content="Reinhard Dummer" /><meta name="DC.Contributor" content="Levi A. Garraway" /><meta name="DC.Date" content="2009 Dec 1" /><meta name="DC.Identifier" content="10.1073/pnas.0905833106" /><meta name="DC.Language" content="en" /><meta property="og:title" content="MEK1 mutations confer resistance to MEK and B-RAF inhibition" /><meta property="og:type" content="article" /><meta property="og:description" content="Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example, the majority of melanomas harbor mutations in the BRAF oncogene, which are predicted to confer enhanced sensitivity to pharmacologic ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777185/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
    


    
        <section class="pmc-alerts">

</section>
    

    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2/">Proc Natl Acad Sci U S A</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/183199/">v.106(48); 2009 Dec 1</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2777185
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pubreader-link other_item"><a href="/pmc/articles/PMC2777185/?report=reader" class="sidefm-pmclink">PubReader</a></li>
<li class="pdf-link other_item"><a href="/pmc/articles/PMC2777185/pdf/zpq20411.pdf" class="int-view">PDF (1.7M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2777185/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2777185/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<div class="collections-button-container" data-article-id="2777185" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="e92dUddu9W4bOSkj1LhC28QD4WY6SARvLdabUv1vREX5dP3fKKoNajCPpHVgy7Hq">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F&amp;text=MEK1%20mutations%20confer%20resistance%20to%20MEK%20and%20B-RAF%20inhibition" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777185/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/19915144/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/19915144/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2777185/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2/">Proc Natl Acad Sci U S A</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/183199/">v.106(48); 2009 Dec 1</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC2777185
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-pnas.png" alt="Logo of pnas" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.pnas.org" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Proc Natl Acad Sci U S A.</span> 2009 Dec 1; 106(48): 20411–20416. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2009 Nov 13. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1073%2Fpnas.0905833106" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1073/pnas.0905833106</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2777185</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19915144">19915144</a></div></div></div><h1 class="content-title">MEK1 mutations confer resistance to MEK and B-RAF inhibition</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Emery%20CM%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156446469728" co-class="co-affbox">Caroline M. Emery</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vijayendran%20KG%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156481159792" co-class="co-affbox">Krishna G. Vijayendran</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zipser%20MC%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156446677440" co-class="co-affbox">Marie C. Zipser</a>,<sup>c</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sawyer%20AM%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438129360" co-class="co-affbox">Allison M. Sawyer</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Niu%20L%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438126048" co-class="co-affbox">Lili Niu</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20JJ%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438122688" co-class="co-affbox">Jessica J. Kim</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hatton%20C%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438119328" co-class="co-affbox">Charles Hatton</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chopra%20R%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438116016" co-class="co-affbox">Rajiv Chopra</a>,<sup>d</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Oberholzer%20PA%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438113568" co-class="co-affbox">Patrick A. Oberholzer</a>,<sup>a,</sup><sup>b,</sup><sup>c,</sup><sup>e</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Karpova%20MB%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438108384" co-class="co-affbox">Maria B. Karpova</a>,<sup>c</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=MacConaill%20LE%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438105984" co-class="co-affbox">Laura E. MacConaill</a>,<sup>a,</sup><sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20J%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438102672" co-class="co-affbox">Jianming Zhang</a>,<sup>f</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20NS%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438100272" co-class="co-affbox">Nathanael S. Gray</a>,<sup>f</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sellers%20WR%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438097872" co-class="co-affbox">William R. Sellers</a>,<sup>d</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156438095472" co-class="co-affbox">Reinhard Dummer</a>,<sup>c</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garraway%20LA%5BAuthor%5D" class="affpopup" co-rid="_co_idm140156481005056" co-class="co-affbox">Levi A. Garraway</a><sup>a,</sup><sup>b,</sup><sup>e,</sup><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140156446469728"><h3 class="no_margin">Caroline M. Emery</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Emery%20CM%5BAuthor%5D">Caroline M. Emery</a></div></div><div id="_co_idm140156481159792"><h3 class="no_margin">Krishna G. Vijayendran</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vijayendran%20KG%5BAuthor%5D">Krishna G. Vijayendran</a></div></div><div id="_co_idm140156446677440"><h3 class="no_margin">Marie C. Zipser</h3><p><sup>c</sup>Department of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zipser%20MC%5BAuthor%5D">Marie C. Zipser</a></div></div><div id="_co_idm140156438129360"><h3 class="no_margin">Allison M. Sawyer</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sawyer%20AM%5BAuthor%5D">Allison M. Sawyer</a></div></div><div id="_co_idm140156438126048"><h3 class="no_margin">Lili Niu</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Niu%20L%5BAuthor%5D">Lili Niu</a></div></div><div id="_co_idm140156438122688"><h3 class="no_margin">Jessica J. Kim</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20JJ%5BAuthor%5D">Jessica J. Kim</a></div></div><div id="_co_idm140156438119328"><h3 class="no_margin">Charles Hatton</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hatton%20C%5BAuthor%5D">Charles Hatton</a></div></div><div id="_co_idm140156438116016"><h3 class="no_margin">Rajiv Chopra</h3><p><sup>d</sup>Novartis Institute of BioMedical Research, Cambridge, MA 02139; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chopra%20R%5BAuthor%5D">Rajiv Chopra</a></div></div><div id="_co_idm140156438113568"><h3 class="no_margin">Patrick A. Oberholzer</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><p><sup>c</sup>Department of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland; </p><p><sup>e</sup>The Broad Institute, Cambridge, MA 02142; and </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Oberholzer%20PA%5BAuthor%5D">Patrick A. Oberholzer</a></div></div><div id="_co_idm140156438108384"><h3 class="no_margin">Maria B. Karpova</h3><p><sup>c</sup>Department of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Karpova%20MB%5BAuthor%5D">Maria B. Karpova</a></div></div><div id="_co_idm140156438105984"><h3 class="no_margin">Laura E. MacConaill</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=MacConaill%20LE%5BAuthor%5D">Laura E. MacConaill</a></div></div><div id="_co_idm140156438102672"><h3 class="no_margin">Jianming Zhang</h3><p><sup>f</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20J%5BAuthor%5D">Jianming Zhang</a></div></div><div id="_co_idm140156438100272"><h3 class="no_margin">Nathanael S. Gray</h3><p><sup>f</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20NS%5BAuthor%5D">Nathanael S. Gray</a></div></div><div id="_co_idm140156438097872"><h3 class="no_margin">William R. Sellers</h3><p><sup>d</sup>Novartis Institute of BioMedical Research, Cambridge, MA 02139; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sellers%20WR%5BAuthor%5D">William R. Sellers</a></div></div><div id="_co_idm140156438095472"><h3 class="no_margin">Reinhard Dummer</h3><p><sup>c</sup>Department of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland; </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D">Reinhard Dummer</a></div></div><div id="_co_idm140156481005056"><h3 class="no_margin">Levi A. Garraway</h3><p><sup>a</sup>Department of Medical Oncology and </p><p><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </p><p><sup>e</sup>The Broad Institute, Cambridge, MA 02142; and </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garraway%20LA%5BAuthor%5D">Levi A. Garraway</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140156485364784_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140156485364784_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140156485364784_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140156485364784_ai" style="display:none"><div class="fm-affl" id="aff1"><sup>a</sup>Department of Medical Oncology and </div><div class="fm-affl" id="aff2"><sup>b</sup>Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; </div><div class="fm-affl" id="aff3"><sup>c</sup>Department of Dermatology, University Hospital of Zurich, Zurich, CH-8091, Switzerland; </div><div class="fm-affl" id="aff4"><sup>d</sup>Novartis Institute of BioMedical Research, Cambridge, MA 02139; </div><div class="fm-affl" id="aff5"><sup>e</sup>The Broad Institute, Cambridge, MA 02142; and </div><div class="fm-affl" id="aff6"><sup>f</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115</div><div id="cor1"><sup>1</sup>To whom correspondence should be addressed. E-mail: <a href="mailto:dev@null" data-email="ude.dravrah.icfd@yawarrag_ivel" class="oemail">ude.dravrah.icfd@yawarrag_ivel</a></div><div id="fn-a.i.b.f.b">Edited by Owen N. Witte, University of California, Los Angeles, CA, and approved September 25, 2009</div><div><p class="p p-first-last">Author contributions: C.M.E., W.R.S., and L.A.G. designed research; C.M.E., K.G.V., A.M.S., J.J.K., M.B.K., and L.E.M. performed research; M.C.Z., P.A.O., and R.D. contributed new reagents/analytic tools; C.M.E., L.N., C.H., R.C., L.E.M., J.Z., N.S.G., W.R.S., and L.A.G. analyzed data; and C.M.E. and L.A.G. wrote the paper.</p></div></div><div class="fm-article-notes hide half_rhythm" id="idm140156485364784_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2009 May 27</div></div><div class="permissions half_rhythm hide" id="idm140156485364784_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">PMC Copyright notice</a> </div><div class="license half_rhythm">Freely available online through the PNAS open access option.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">
               Supporting Information
            </div>
            
            <div><a href="/pmc/articles/PMC2777185/bin/supp_106_48_20411__index.html" data-ga-action="click_feat_suppl">supp_106_48_20411__index.html</a><span style="color:gray"> (673 bytes)</span></div><div class="small guid">GUID: CC36C475-9C35-45DE-AC5F-BB81B83ABDE2</div>
            <div><a href="/pmc/articles/PMC2777185/bin/0905833106_0905833106SI.pdf" data-ga-action="click_feat_suppl">0905833106_0905833106SI.pdf</a><span style="color:gray"> (2.1M)</span></div><div class="small guid">GUID: 2CDF1235-EDAE-4E28-B6A8-A68AE717F6E8</div>
         </div></dd></dl></div><div id="abstract-a.i.b.q" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.i.b.qtitle" style="text-transform: uppercase;">Abstract</h2><!--article-meta--><div><p class="p p-first-last">Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example, the majority of melanomas harbor mutations in the <em>BRAF</em> oncogene, which are predicted to confer enhanced sensitivity to pharmacologic MAP kinase inhibition (e.g., RAF or MEK inhibitors). We investigated the clinical relevance of MEK dependency in melanoma by massively parallel sequencing of resistant clones generated from a <em>MEK1</em> random mutagenesis screen in vitro, as well as tumors obtained from relapsed patients following treatment with AZD6244, an allosteric MEK inhibitor. Most mutations conferring resistance to MEK inhibition in vitro populated the allosteric drug binding pocket or &#x003b1;-helix C and showed robust (&#x02248;100-fold) resistance to allosteric MEK inhibition. Other mutations affected MEK1 codons located within or abutting the N-terminal negative regulatory helix (helix A), which also undergo gain-of-function germline mutations in cardio-facio-cutaneous (CFC) syndrome. One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244. Both MEK1(P124L) and MEK1(Q56P), which disrupts helix A, conferred cross-resistance to PLX4720, a selective B-RAF inhibitor. However, exposing <em>BRAF</em>-mutant melanoma cells to AZD6244 and PLX4720 in combination prevented emergence of resistant clones. These results affirm the importance of MEK dependency in <em>BRAF</em>-mutant melanoma and suggest novel mechanisms of resistance to MEK and B-RAF inhibitors that may have important clinical implications.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">BRAF, drug resistance, MAP kinase, melanoma</span></div></div><div id="body-a.j" class="tsec sec"><h2 class="headless nomenu"></h2><p class="p p-first">Approximately one-third of all cancers harbor genetic alterations that aberrantly upregulate mitogen-activated protein kinase (MAPK)-dependent signal transduction (<a href="#B1" rid="B1" class=" bibr popnode">1</a>). In the MAPK pathway, RAS oncoproteins activate RAF, MEK, and ERK kinases to direct key cell proliferative and survival signals. When rendered constitutively active by genetic mutation, the MAP kinase pathway is believed to confer &#x0201c;oncogene dependency&#x0201d; (<a href="#B2" rid="B2" class=" bibr popnode">2</a>), an excessive reliance on its dysregulated activity for tumor viability. Therefore, protein kinases within this signaling cascade offer promising targets for novel anticancer therapeutics.</p><p>In melanoma, uncontrolled MAP kinase pathway activity is nearly ubiquitous and occurs most commonly through gain-of-function mutations involving codon 600 of the B-RAF kinase (<a href="#B3" rid="B3" class=" bibr popnode">3</a>) (<em>BRAF<sup>V600E</sup></em>; 50&#x02013;70% of cases). Considerable preclinical evidence has associated the <em>BRAF<sup>V600E</sup></em> mutation with heightened sensitivity to pharmacologic inhibition of RAF or MEK kinases (<a href="#B4" rid="B4" class=" bibr popnode">4</a>, <a href="#B5" rid="B5" class=" bibr popnode">5</a>). Although early clinical trials of RAF and MEK inhibitors failed to show a substantial benefit (<a href="#B6" rid="B6" class=" bibr popnode">6</a>, <a href="#B7" rid="B7" class=" bibr popnode">7</a>), recent phase I studies of selective RAF inhibitors have shown promising results in patients with <em>BRAF</em>-mutant tumors (<a href="#B8" rid="B8" class=" bibr popnode">8</a>, <a href="#B9" rid="B9" class=" bibr popnode">9</a>). Thus, optimizing therapeutic efficacy while avoiding or bypassing the emergence of resistance to MAP kinase pathway inhibition will likely gain increasing importance in melanoma and other MAP kinase-driven cancers.</p><p class="p">Here, we describe the use of random mutagenesis and massively parallel sequencing to identify mutations within MEK kinase that promote resistance to pharmacologic MEK inhibition. This deep sequencing approach was also leveraged to interrogate melanomas derived from patients treated with the investigational MEK inhibitor AZD6244. Structural and functional characterization of the resulting MEK1 resistance mutations highlighted two major types of resistance to allosteric MEK inhibition, one of which confers cross-resistance to selective B-RAF inhibition. These results may therefore inform a clinical understanding of resistance to MEK and RAF inhibition, as well as approaches to prevent its emergence during targeted treatment.</p></div><div id="sec-a.j.d" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.j.dtitle" style="text-transform: uppercase;">Results</h2><div id="sec-a.j.d.b" class="sec sec-first"><p></p><h3 id="sec-a.j.d.btitle" class="inline">Comprehensive Identification of <em>MEK1</em> Resistance Mutations in Vitro. </h3><p class="p p-first">To begin to characterize resistance to MAP kinase pathway inhibition in the context of <em>BRAF<sup>V600E</sup></em> melanoma, we used a random mutagenesis screen (<a href="#B10" rid="B10" class=" bibr popnode">10</a>) together with massively parallel sequencing (<a href="#B11" rid="B11" class=" bibr popnode">11</a>) to discover the spectrum of variants associated with resistance to allosteric MEK inhibition in vitro. We expressed a saturating cDNA library of <em>MEK1</em> mutations in A375 melanoma cells, which harbor the <em>BRAF<sup>V600E</sup></em> mutation and are highly sensitive to MEK inhibition. After culturing these cells for 4 weeks in the presence of a diarylamine MEK inhibitor (<a href="#B12" rid="B12" class=" bibr popnode">12</a>, <a href="#B13" rid="B13" class=" bibr popnode">13</a>) (either 1.5 &#x003bc;M AZD6244 or 2 &#x003bc;M CI-1040), resistant clones emerged, &#x02248;1,000 of which were pooled and characterized en masse by massively parallel sequencing (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a> for a full description). An additional 100 clones were sequenced by the Sanger method. A complete set of mutant MEK1 alleles and the methods of identification are listed in <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S1</a>. This combined analysis of &#x02248;1,100 resistant clones vastly exceeded the scope of prior mutagenesis studies (<a href="#B14" rid="B14" class=" bibr popnode">14</a>) and offered a comprehensive framework for unbiased characterization of <em>MEK1</em>-mediated drug resistance.</p><p>The landscape of <em>MEK1</em> mutations that emerged in the presence of AZD6244 is shown in <a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a><em>A</em>. Similar results were obtained from mutatgenesis experiments using CI-1040 (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S1<em>A</em></a>). We investigated the distribution of candidate resistance alleles across each <em>MEK1</em> nucleotide position and mapped the resulting amino acid substitutions within the three-dimensional structure of the full-length MEK1 kinase domain (<a href="#B15" rid="B15" class=" bibr popnode">15</a>) (PDB code: <span>3EQC</span>) (<a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a><em>B</em>; see also <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S1<em>B</em></a> for a larger view).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140156484092384"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2787162_zpq9990902560001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is zpq9990902560001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2777185/bin/zpq9990902560001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140156484092384"><a target="object" rel="noopener" href="/pmc/articles/PMC2777185/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2777185/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig. 1.</a></div><!--caption a7--><div class="caption"><p>Candidate <em>MEK1</em> resistance mutations. (<em>A</em>) The average variant score of candidate mutations across the <em>MEK1</em> coding sequence from the AZD6244 mutagenesis screen (based on one lane of Illumina sequencing) is shown. The corresponding amino acid substitutions from high scoring mutations (&#x0003e;15%) are indicated in bold. (<em>B</em>) The locations of putative MEK1 inhibitor resistance alleles are indicated within the crystal structure of MEK1 (blue). Both ATP and an arylamine MEK inhibitor (PD318088; purple) are shown to bind MEK1; this inhibitor chemotype binds a hydrophobic pocket adjacent to the ATP binding site. Helix C (green) and helix A (red) are indicated. Mutations within the MEK1 allosteric binding pocket (<em>C</em>), along or adjacent to helix C, are shown in green (<em>D</em>) or within/interfacing with helix A, are shown in red as a protein surface (<em>E</em>).</p></div></div></div><p>Putative MEK1 resistance alleles segregated into two classes: &#x0201c;primary&#x0201d; mutations clustering within or directly perturbing the allosteric binding pocket and &#x0201c;secondary&#x0201d; mutations that resided outside of the drug binding region. Primary MEK1 resistance alleles could be further subdivided into mutations situated directly within the arylamine binding pocket (e.g., I99T, L115P/R, G128D, F129L, V211D, and L215P; <a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a><em>C</em>) and a distinct set located in the second protein shell, along and adjacent to the C helix (e.g., I103N, K104N, I111N, H119P, E120D, F133L; <a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a><em>D</em>). Notably, the MEK1 hydrophobic pocket includes residues from both &#x003b1;-helix C and the activation loop. Binding of arylamine inhibitors within this pocket prevents the structural reorganization of &#x003b1;-helix C and other motifs, which generates a catalytically active MEK1 conformation. Thus, primary mutations may cause resistance either by direct interference or through altered C helix conformation.</p><p class="p p-last">The secondary class of resistance mutations populated two regions of MEK1. One region includes the N-terminal negative regulatory domain known as helix A (<a href="#B15" rid="B15" class=" bibr popnode">15</a>) (e.g., Q56P) and a proline proximal to the C helix (P124) that abuts helix A (<a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a><em>E</em>). P124 mutations were identified either by Sanger sequencing of individual resistant clones (P124S) or by deep sequencing (P124Q), albeit at an average variant score that fell beneath the initial threshold for detection (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S1</a>). The proximity of Q56 and P124 to the N-terminal negative regulatory domain (<a href="/pmc/articles/PMC2777185/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a> <em>B</em> and <em>E</em>) suggests a resistance mechanism that involves upregulation of intrinsic MEK1 kinase activity. Toward this end, the Q56P and P124S mutations closely mimic T55P and P124L, respectively&#x02014;two germline variants observed in patients with cardio-facio-cutaneous (CFC) syndrome (<a href="#B15" rid="B15" class=" bibr popnode">15</a>, <a href="#B16" rid="B16" class=" bibr popnode">16</a>) that confer aberrant MEK activation. The D67N mutation, which was identified in the CI-1040 mutagenesis screen (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S1<em>A</em></a>), also occurs as a germline CFC variant (<a href="#B17" rid="B17" class=" bibr popnode">17</a>) and has occasionally been detected as a somatic cancer mutation (<a href="#B18" rid="B18" class=" bibr popnode">18</a>). The other secondary region involves the C-terminal kinase domain (e.g., G328R, P326L, and E368K); the functional significance of these mutations is currently unknown. On the basis of these findings, we reasoned that on-target resistance to allosteric MEK inhibition may arise through reduction of drug binding affinity or enhanced intrinsic MEK1 activation.</p></div><div id="sec-a.j.d.c" class="sec"><p></p><h3 id="sec-a.j.d.ctitle" class="inline">Functional Validation of <em>MEK1</em> Resistance Alleles. </h3><p class="p p-first">To confirm the functional effects of putative <em>MEK1</em> resistance alleles identified by random mutagenesis, we introduced several representative mutations into the sequence of wild-type MEK1 and expressed the mutant cDNAs in parental A375 melanoma cells. All variant constructs were expressed at comparable levels (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S1<em>C</em></a>). As expected, A375 cells expressing wild-type MEK1 (MEK-WT) or a constitutively active variant (MEK-DD) showed CI-1040 GI<sub>50</sub> values comparable to that of wild-type A375 cells (&#x02248;100 nM; <a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a><em>A</em>). In contrast, all primary resistance alleles examined (I103N, L115P, F129L, and V211D) increased CI-1040 and AZD6244 GI<sub>50</sub> values by 50- to 1,000-fold (<a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a> <em>A</em> and <em>B</em>). The secondary resistance allele Q56P also conferred &#x02248;100-fold resistance to MEK inhibition (<a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a> <em>A</em> and <em>B</em>), whereas the effect of the P124S allele was significant but less pronounced (4- to 10-fold; <a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a> <em>A</em> and <em>B</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S2</a>). The Q56P mutation also increased MEK kinase activity in vitro (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S2</a>). Several other resistance alleles had little effect on kinase activity in vitro (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S2</a>); however, subtle kinase effects in vivo cannot be excluded.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140156483497776"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2787162_zpq9990902560002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is zpq9990902560002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2777185/bin/zpq9990902560002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140156483497776"><a target="object" rel="noopener" href="/pmc/articles/PMC2777185/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2777185/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Fig. 2.</a></div><!--caption a7--><div class="caption"><p>Functional characterization of <em>MEK1</em> resistance mutations identified in vitro. Growth inhibition curves of parental A375 (solid black), A375 cells expressing primary or secondary MEK1 resistance alleles, a constitutive active MEK variant (MEK-DD; grey), or wild-type <em>MEK1</em> (hatched black) are shown for CI-1040 (<em>A</em>) or AZD6244 (<em>B</em>). (<em>C</em>) The levels of pERK1/2, pMEK1/2, MEK1/2, and &#x003b1;-tubulin are shown for A375 cells expressing MEK1 mutations following 16-hour incubation with CI-1040 at 10 &#x003bc;M, 5 &#x003bc;M, 2 &#x003bc;M, 0.4 &#x003bc;M, 0.08 &#x003bc;M, and 0 &#x003bc;M.</p></div></div></div><p class="p p-last">Biochemical studies of MEK inhibition corroborated the pharmacologic results above. Treatment with CI-1040 or AZD6244 potently inhibited ERK phosphorylation (<em>p</em>-ERK) in both parental A375 cells and those expressing MEK-WT or MEK-DD, but this effect was markedly attenuated in cells expressing each resistant allele (<a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a><em>C</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF3" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S3<em>A</em></a>). The presence of MEK1 mutations strongly diminished both the magnitude and durability of MEK inhibition (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF3" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S3<em>B</em></a>). In several instances, levels of MEK phosphorylation (<em>p</em>-MEK) increased at higher doses of MEK inhibitor (e.g., A375, MEK-WT, and MEK(V211D); <a href="/pmc/articles/PMC2777185/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a><em>C</em>), consistent with modulation of feedback inhibition (<a href="#B19" rid="B19" class=" bibr popnode">19</a>). Together, these results validated the functional relevance of MEK1 mutations identified by random mutagenesis.</p></div><div id="sec-a.j.d.d" class="sec"><p></p><h3 id="sec-a.j.d.dtitle" class="inline">An Acquired <em>MEK1</em> Mutation in AZD6244-Resistant Melanoma. </h3><p class="p p-first">To determine whether any aforementioned resistance mechanisms might influence the clinical response to MEK inhibition, we used targeted deep sequencing of tumors from melanoma patients treated with MEK inhibitors. We reasoned that <em>MEK1</em> exons 3 and 6, which encompass the validated resistant alleles described above (<a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a><em>A</em>), might represent promising candidate loci for the clinical emergence of resistance to MEK inhibition. Accordingly, we characterized the <em>MEK1</em> locus in tumor genomic DNA from advanced melanoma patients enrolled in a phase II clinical trial of AZD6244 (<a href="#B20" rid="B20" class=" bibr popnode">20</a>). <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST3" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S3</a> summarizes the pertinent clinical characteristics of the patients examined. Seven patients were identified who experienced transient disease stabilization followed by relapse on AZD6244 (mean stable disease duration = 55 &#x000b1; 18 days in patients 1&#x02013;6). Five patients contained lymph node or dermal metastases amenable to both pretreatment and postrelapse biopsy, and three harbored <em>BRAF<sup>V600E</sup></em> melanomas. One patient with <em>BRAF<sup>V600E</sup></em> melanoma (patient 7) experienced prolonged disease stabilization on AZD6244.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140156483475280"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2787162_zpq9990902560003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is zpq9990902560003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2777185/bin/zpq9990902560003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140156483475280"><a target="object" rel="noopener" href="/pmc/articles/PMC2777185/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC2777185/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Fig. 3.</a></div><!--caption a7--><div class="caption"><p>An acquired <em>MEK1</em> mutation in AZD6244-resistant metastatic melanoma. PCR products corresponding to <em>MEK1</em> exons 3 and 6 (<em>A</em>) were generated from relapsed melanomas treated with AZD6244; products were pooled and interrogated by massively parallel sequencing (a single Illumina lane). (<em>B</em>) A single mutation, <em>MEK1<sup>P124L</sup></em>, was recovered by this analysis. (<em>C</em>) Sanger sequencing chromatograms from <em>MEK1</em> exon 3 corresponding to pretreatment and postrelapse melanoma DNA from patient 7 are shown. A C &#x0003e; T transition, indicative of <em>MEK1<sup>P124L</sup></em>, is evident only in the relapsed sample. (<em>D</em>) Changes in RECIST total count (blue graph) and serum S100 levels (red graph) are plotted over the clinical course of patient 7. The times of pretreatment and postrelapse biopsies are indicated. The intervals of temozolomide treatment (shaded blue) and AZD6244 treatment (shaded pink) are shown.</p></div></div></div><p><em>MEK1</em> exons 3 and 6 were amplified by PCR using tumor genomic DNA from five patients who relapsed following MEK inhibitor treatment. All PCR products were pooled and subjected to massively parallel sequencing (see <em>Experimental Procedures</em>). This analysis identified a C &#x02192; T transition in <em>MEK1</em> exon 3 that encodes a P124L substitution (<a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a><em>B</em>). MEK1 codon 124 was implicated as a secondary resistance allele during the random mutagenesis screens, although alternative amino acid substitutions (P124S or P124Q) were selected. Sanger sequencing of individual pretreatment and postrelapse melanoma samples revealed that <em>MEK1<sup>P124L</sup></em> occurred in the postrelapse tumor DNA from patient 7 but was absent in the pretreatment tumor sample (<a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a><em>C</em>). This finding suggested that mutations within the drug target might provide a clinically relevant means of resistance to MEK inhibitors.</p><p class="p p-last">The <em>MEK1<sup>P124L</sup></em> allele was identified in a 55-year-old male with metastatic melanoma, including pulmonary and skeletal involvement at the time of clinical trial enrollment. The patient was treated with oral temozolomide (435 mg per day) but developed progressive disease characterized by mediastinal lymph node enlargement and pulmonary infiltration (<a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a><em>D</em>). In accordance with protocol specifications, the patient was switched to the AZD6244 treatment arm. This resulted in regression or stabilization of all disease sites except for a left axillary lymph node metastasis, which expanded over a period of 16 weeks with a concomitant rise in the serum S100 tumor marker. Surgical removal of this metastasis led to a marked decrease in S100 levels; <em>MEK1<sup>P124L</sup></em> was detected in this specimen. Following resection, the patient continued on AZD6244 and showed prolonged disease stabilization (&#x0003e;44 weeks), including a steadily declining RECIST score and a 28% overall reduction in tumor burden (<a href="/pmc/articles/PMC2777185/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a><em>D</em>).</p></div><div id="sec-a.j.d.e" class="sec"><p></p><h3 id="sec-a.j.d.etitle" class="inline">Ex Vivo and Functional Analysis of MEK1(P124L). </h3><p class="p p-first">To confirm the role of the P124L allele in resistance to MEK inhibition, we examined the effects of MEK inhibition on ex vivo melanoma cultures derived from the AZD6244-resistant metastasis of patient 7 (M307 cells). M307 cells were obtained from the left axillary lymph node at the same time as the postrelapse resection described above (see <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>). The presence of <em>MEK1<sup>P124L</sup></em> in M307 was verified by Sanger sequencing (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF4" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S4</a>). The GI<sub>50</sub> for AZD6244 was 10&#x02013;50 nM in treatment-na&#x000ef;ve <em>BRAF<sup>V600E</sup></em> melanoma cultures (WM3482, WM3457, and WM3506) but exceeded 2 &#x003bc;M in cells derived from the AZD6244-resistant metastasis (M307; <a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a><em>A</em>). Likewise, marked biochemical inhibition of <em>p</em>-ERK was achieved following a 16-hour exposure to &#x02248;400 nM AZD6244 in treatment-na&#x000ef;ve lines, but <em>p</em>-ERK remained robust in the resistant cells even at 10 &#x003bc;M AZD6244 (<a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a><em>B</em>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140156480290112"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2787162_zpq9990902560004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is zpq9990902560004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2777185/bin/zpq9990902560004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140156480290112"><a target="object" rel="noopener" href="/pmc/articles/PMC2777185/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC2777185/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Fig. 4.</a></div><!--caption a7--><div class="caption"><p>Ex vivo and functional characterization of MEK1(P124L). (<em>A</em>) AZD6244-mediated growth inhibition ex vivo of treatment-na&#x000ef;ve <em>BRAF<sup>V600E</sup></em> melanoma cells (black and blue) or cells cultured from an AZD6244-resistant metastatic focus (red). (<em>B</em>) ERK phosphorylation (<em>p</em>-ERK) and MEK phosphorylation (<em>p</em>-MEK) are shown following treatment with increasing concentrations of AZD6244 in treatment-na&#x000ef;ve or AZD6244-resistant melanoma cells cultured ex vivo. The tubulin loading control (&#x003b1;-tubulin) is also shown. (<em>C</em>) AZD6244 growth inhibition curves of parental A375 (solid black), A375 cells expressing MEK-DD (grey), wild-type <em>MEK1</em> (hatched black), or MEK1(P124L) (red) are shown. In each instance <em>n</em> = 6 and &#x000b1; error = standard deviation. (<em>D</em>) <em>p</em>-ERK and <em>p</em>-MEK are shown following treatment with increasing AZD6244 concentrations in the cell lines described in <em>C</em>, <em>Above</em>. The &#x003b1;-tubulin control is also shown.</p></div></div></div><p class="p p-last">Next, we introduced recombinant MEK1(P124L) into parental A375 cells and examined pharmacological resistance to MEK inhibition. As observed with the MEK1(P124S) allele above, MEK1(P124L) expression resulted in an &#x02248;5-fold increase in AZD6244 GI<sub>50</sub> when compared to A375, MEK-WT, or MEK-DD (<a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a><em>C</em>). Similarly, MEK1(P124L) conferred sustained <em>p</em>-ERK expression following exposure to varying concentrations of MEK inhibitor, with measureable <em>p</em>-ERK even at 2 &#x003bc;M of AZD6244 (<a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a><em>D</em>). In contrast, parental A375 cells and those expressing MEK-WT and MEK-DD showed diminished <em>p</em>-ERK levels even at the lowest drug concentration (80 nM; <a href="/pmc/articles/PMC2777185/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Fig. 4</span></a><em>D</em>).</p></div><div id="sec-a.j.d.f" class="sec"><p></p><h3 id="sec-a.j.d.ftitle" class="inline">Secondary MEK1 Mutations Confer Cross-Resistance to B-RAF Inhibition. </h3><p class="p p-first">Given the high prevalence of oncogenic <em>BRAF</em> mutations in melanoma, several RAF inhibitors have entered clinical trials (<a href="#B8" rid="B8" class=" bibr popnode">8</a>, <a href="#B9" rid="B9" class=" bibr popnode">9</a>, <a href="#B21" rid="B21" class=" bibr popnode">21</a>). To determine whether MEK1 mutations confer cross-resistance to RAF inhibition, we examined the effects of the selective B-RAF inhibitor PLX4720 (<a href="#B21" rid="B21" class=" bibr popnode">21</a>) in the cultured melanoma lines described above. AZD6244-resistant primary melanoma cells (M307) demonstrated profound cross-resistance to PLX4720, with a GI<sub>50</sub> value of &#x0003e;10 &#x003bc;M compared to 5&#x02013;10 nM in treatment-na&#x000ef;ve lines (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>A</em>). These findings were reflected in biochemical studies of <em>p</em>-MEK following B-RAF inhibition (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF5" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S5<em>A</em></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140156439047888"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2787162_zpq9990902560005.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is zpq9990902560005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2777185/bin/zpq9990902560005.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140156439047888"><a target="object" rel="noopener" href="/pmc/articles/PMC2777185/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC2777185/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Fig. 5.</a></div><!--caption a7--><div class="caption"><p>Effects of B-RAF and combined MEK/BRAF inhibition on MEK1 resistance alleles. (<em>A</em>) PLX4720-mediated growth inhibition curves are shown for ex vivo cultures of treatment-na&#x000ef;ve <em>B-RAF<sup>V600E</sup></em> melanoma cells (black) or cells cultured from an AZD6244-resistant metastatic focus (red). (<em>B</em>) PLX4720 growth inhibition curves are shown for parental A375 cells (solid black) and A375 cells expressing selected primary MEK1 resistance alleles (blue), MEK-DD (grey), wild-type <em>MEK1</em> (hatched black), MEK1(Q56P), or MEK1(P124L) (red). In each instance, <em>n</em> = 6 and &#x000b1; error = standard deviation. (<em>C</em>) Colony formation assays are shown for parental A375 (red bars) and cells expressing empty vector (orange bars), MEK-WT (green bars), MEK(DD) (pink bars), or MEK(P124L) (blue bars), as indicated in the legend <em>Inset</em>. Concentrations of AZD6244 and PLX4720 (&#x003bc;M) are indicated (<em>Below</em>). <em>y</em>-axis indicates the number of dense colonies formed compared to the vehicle control for each case. <em>n</em> = 3 and &#x000b1; error = standard deviation.</p></div></div></div><p class="p p-last">In general, expression of primary MEK1 resistance alleles identified in vitro only modestly affected the PLX4720 GI<sub>50</sub> in A375 cells (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>B</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S2</a>). However, the P124L and P124S mutations conferred a two- to threefold resistance relative to wild-type MEK1 (approximately three- to fourfold resistance compared to parental A375), and the Q56P mutation conferred robust resistance (&#x0003e;50-fold) to PLX4720, comparable to the MEK(DD) allele (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>B</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S2</a>). Levels of <em>p</em>-MEK following PLX4720 treatment showed comparable reduction across all MEK1 resistance alleles (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF5" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S5<em>B</em></a>). Overall, these results indicated that clinically relevant MEK1 resistance mutations may confer cross-resistance to B-RAF inhibition.</p></div><div id="sec-a.j.d.g" class="sec sec-last"><p></p><h3 id="sec-a.j.d.gtitle" class="inline">Combined B-RAF and MEK Inhibition Prevents the Emergence of Resistant Clones. </h3><p class="p p-first">Finally, we tested whether the stringency of MAP kinase pathway inhibition might influence the emergence of on-target resistance variants. A375 melanoma cells expressing empty vector or various derivatives were cultured for up to 4 weeks in the presence of varying doses of AZD6244 or PLX4720 singly or in combination, and colony formation was monitored (see <em>Materials and Methods</em>). Exposure to AZD6244 completely suppressed the growth of parental A375 cells and those expressing empty vector or MEK(DD) at all concentrations examined (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>C</em>). Expression of wild-type MEK1 resulted in low-level breakthrough growth under these conditions (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF6" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S6</a>; see <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>), but only marginally affected MEK inhibitor GI<sub>50</sub> values compared to parental A375 (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=ST2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S2</a>). In contrast, expression of MEK1(P124L) resulted in numerous resistant colonies at 0.5 &#x003bc;M and 0.25 &#x003bc;M of AZD6244 (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>C</em>). As expected, cells expressing the mutagenized MEK1-cDNA library that was used in the primary resistance screens formed some AZD6244-resistant colonies at all concentrations tested (<a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF6" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S6</a>).</p><p class="p p-last">As with AZD6244, the B-RAF inhibitor PLX4720 also suppressed the growth of wild-type and empty vector-expressing A375 melanoma cells. On the other hand, MEK1(P124L) expression yielded PLX4720-resistant colonies at all concentrations tested (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>C</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF6" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S6</a>). In this assay, the magnitude of MEK1(P124L)-mediated resistance to B-RAF inhibition approached that seen following MEK(DD) expression (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>C</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF6" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S6</a>). These results complemented the MEK1(P124L) growth inhibition studies above. Strikingly, however, combined exposure to both AZD6244 and PLX4720 potently suppressed the emergence of resistant variants at 0.5&#x02013;1.5 &#x003bc;M of each compound (<a href="/pmc/articles/PMC2777185/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Fig. 5</span></a><em>C</em> and <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=SF6" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Fig. S6</a>). These results raised the possibility that combined RAF and MEK inhibition might circumvent acquired resistance to targeted therapeutics directed against the MAP kinase pathway.</p></div></div><div id="sec-a.j.e" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.j.etitle" style="text-transform: uppercase;">Discussion</h2><p class="p p-first">Tumors harboring a &#x0201c;druggable&#x0201d; oncogene dependency often develop on-target clinical resistance through point mutation or genomic amplification of the target locus (<a href="#B22" rid="B22" class=" bibr popnode">22</a><a href="#B23" rid="B23" class=" bibr popnode"></a>&#x02013;<a href="#B24" rid="B24" class=" bibr popnode">24</a>). Elaboration of such resistance mechanisms has enabled the design of second-generation inhibitors with enhanced potency against a range of resistant variants (<a href="#B25" rid="B25" class=" bibr popnode">25</a>, <a href="#B26" rid="B26" class=" bibr popnode">26</a>). In this study, we used a systematic approach that combined random mutagenesis and massively parallel sequencing to characterize on-target resistance to MEK inhibition in melanoma.</p><p>Most MEK1 resistance alleles that emerged from in vitro screens populate the allosteric drug binding pocket adjacent to the ATP binding motif or the second protein shell situated within or near helix C. Arylamine MEK inhibitors function by locking the kinase into a &#x0201c;closed&#x0201d; inactive conformation, in which the activation loop causes helix C to become externally rotated and displaced (<a href="#B27" rid="B27" class=" bibr popnode">27</a>). Thus, primary MEK1 mutations may introduce resistance through direct interference of drug binding or by forcing helix C toward a closed conformation that disrupts the binding pocket. Conceivably, the design of ATP-competitive inhibitors, which have proved successful in tyrosine kinase-driven cancers, may offer one approach to override resistance to non-ATP-competitive kinase inhibition.</p><p>Numerous candidate MEK1 resistance alleles identified in vitro reside outside of the drug binding pocket, localizing to regions such as the C-terminal kinase domain or the interface between helix A and the core kinase domain (<a href="#B15" rid="B15" class=" bibr popnode">15</a>). Notably, several such secondary mutations correspond closely to missense germline variants that are observed in CFC syndrome (<a href="#B28" rid="B28" class=" bibr popnode">28</a>). This disorder is characterized by mental retardation as well as cardiac and facial abnormalities and results from aberrant MAP kinase signaling during development. Consistent with the fact that several CFC alleles are known to enhance MEK kinase activity, the Q56P and P124S/L mutations demonstrated a substantial resistance phenotype as measured by pharmacologic growth inhibition studies. These mutations may modulate intrinsic MEK kinase activity in a manner that becomes expressly manifest in vivo during prolonged exposure to arylamine MEK inhibition.</p><p>Guided by resistance alleles identified in vitro, we analyzed the <em>MEK1</em> locus in melanoma patients who relapsed during treatment with the small-molecule MEK inhibitor AZD6244. These studies identified the <em>MEK1<sup>P124L</sup></em> mutation in a metastatic focus that progressed in the context of otherwise stable disease on AZD6244. The proline residue at codon 124 is uniquely positioned such that it may exert an indirect influence on helix C conformation while also interfacing directly with helix A, a negative regulatory motif whose crystal structure was recently solved (<a href="#B15" rid="B15" class=" bibr popnode">15</a>). We speculate that mutation of this proline may disrupt a key regulatory interaction between helix A and the rest of the kinase, while simultaneously altering helix C indirectly through loss of a turn motif proximal to this segment. These results illuminate clinical mechanisms of resistance to both MEK and B-RAF inhibition and may inform rational therapeutic approaches to target this prominent tumor dependency. More generally, this work also highlights the power of systematic tumor tissue procurement both before treatment and following relapse in clinical trials of targeted anticancer agents.</p><p>The clinical emergence of a resistant <em>MEK1</em> mutation in metastatic <em>BRAF<sup>V600E</sup></em> melanoma suggests that the prior failure of first-generation RAF or MEK inhibitors to elicit meaningful tumor responses in many <em>BRAF<sup>V600E</sup></em> melanomas may have resulted at least in part from suboptimal drug potency or pharmacodynamics in vivo. This notion is supported by recent phase I clinical trial results using selective RAF inhibitors, in which favorable drug pharmacodynamics correlated strongly with clinical response (<a href="#B8" rid="B8" class=" bibr popnode">8</a>, <a href="#B9" rid="B9" class=" bibr popnode">9</a>). Whether the MEK dependency observed in <em>BRAF</em>-mutant melanomas is manifest in other MAP kinase-driven contexts remains an open question. Preclinical studies suggest that some <em>NRAS</em>-mutant melanomas may also exhibit sensitivity to RAF or MEK inhibition (<a href="#B4" rid="B4" class=" bibr popnode">4</a>, <a href="#B29" rid="B29" class=" bibr popnode">29</a>), whereas <em>KRAS</em> mutations have conferred only marginal sensitivity (<a href="#B30" rid="B30" class=" bibr popnode">30</a>). These findings may point to the future need to target multiple cellular pathways simultaneously (e.g., combined MAP kinase and PI3 kinase pathway blockade). On the other hand, combined pharmacologic blockade within the MAPK pathway may suppress the emergence of on-target resistance in tumors harboring the <em>BRAF<sup>V600E</sup></em> mutation.</p><p class="p p-last">Finally, these findings highlight the increasing importance of tumor genomic profiling to guide patient selection in clinical trials of targeted therapeutics (<a href="#B31" rid="B31" class=" bibr popnode">31</a>). The presence of <em>BRAF</em> mutations is expected to denote patient subpopulations whose tumors are enriched for RAF/MEK dependency. In the future, profiling <em>BRAF</em>-mutant melanomas for genetic alterations affecting <em>MEK1</em> (and conceivably <em>MEK2</em>) in cases where resistance emerges may be required both to determine the mechanism of resistance and to specify optimal salvage therapy. Robust diagnostic approaches to stratify patients on the basis of tumor genotype and to identify clinically pertinent resistance mechanisms should speed the advent of &#x0201c;personalized&#x0201d; cancer treatment.</p></div><div id="sec-a.j.f" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.j.ftitle" style="text-transform: uppercase;">Experimental Procedures</h2><div id="sec-a.j.f.b" class="sec sec-first"><p></p><h3 id="sec-a.j.f.btitle" class="inline">Cell Lines and Primary Melanoma Cultures. </h3><p class="p p-first-last">The origins and growth conditions of all cell lines used are described in the <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>.</p></div><div id="sec-a.j.f.c" class="sec"><p></p><h3 id="sec-a.j.f.ctitle" class="inline">MEK1 Random Mutagenesis Screen. </h3><p class="p p-first-last">Generation of mutagenized libraries was accomplished using a modification of published methods (<a href="#B10" rid="B10" class=" bibr popnode">10</a>), and is described in the <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>.</p></div><div id="sec-a.j.f.d" class="sec"><p></p><h3 id="sec-a.j.f.dtitle" class="inline">Sequencing of <em>MEK1</em> DNA. </h3><p class="p p-first-last">MEK1 cDNA or exons 3 and 6 of MEK1 genomic DNA were characterized by second generation sequencing or Sanger sequencing as described in the <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>.</p></div><div id="sec-a.j.f.e" class="sec"><p></p><h3 id="sec-a.j.f.etitle" class="inline">Retroviral Infections. </h3><p class="p p-first-last">293T cells (70% confluent) were transfected with pWZL-Blast-MEK1 and pCL-Ampho packaging vector using Lipofectamine 2000 (Invitrogen). Supernatants containing virus were passed through a 0.45-&#x003bc;m syringe. The A375 cells were infected for 16 h with virus together with polybrene (4 &#x003bc;g/mL, Sigma). The selective marker blasticidin (3 &#x003bc;g/mL) was introduced 48 h postinfection.</p></div><div id="sec-a.j.f.f" class="sec"><p></p><h3 id="sec-a.j.f.ftitle" class="inline">In Vitro Pharmacologic Studies. </h3><p class="p p-first-last">CI-1040 (<a href="#B13" rid="B13" class=" bibr popnode">13</a>) was purchased from Shanghai Lechen International Trading Company; AZD6244 (<a href="#B12" rid="B12" class=" bibr popnode">12</a>) was purchased from Selleck Chemicals, and PLX4720 (<a href="#B21" rid="B21" class=" bibr popnode">21</a>) was purchased from Symansis. Cell growth inhibition assays were performed as described in the <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>.</p></div><div id="sec-a.j.f.g" class="sec"><p></p><h3 id="sec-a.j.f.gtitle" class="inline">Colony Formation Assays. </h3><p class="p p-first-last">For each cell line, 40,000 cells where seeded into 15-cm dishes in triplicate, and colony formation was characterized as described in the <a href="http://www.pnas.org/cgi/data/0905833106/DCSupplemental/Supplemental_PDF#nameddest=STXT" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank"><em>SI Text</em></a>.</p></div><div id="sec-a.j.f.h" class="sec sec-last"><p></p><h3 id="sec-a.j.f.htitle" class="inline">Patients and Samples. </h3><p class="p p-first-last">Pretreatment and postrelapse metastatic melanoma samples were obtained from patients enrolled in a phase II clinical trial of AZD6244 (<a href="#B20" rid="B20" class=" bibr popnode">20</a>). Consent was received from all patients according to the approved biobanking IRB protocol (University of Z&#x000fc;rich, no. 647) before biopsy.</p></div></div><div id="sec-a.j.g" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="sec-a.j.gtitle" style="text-transform: uppercase;">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="PMC_1">
            
               <!--caption a9--><strong>Supporting Information:</strong>
            
            <div class="sup-box half_rhythm" id="media-a.j.g.b.b"><a href="/pmc/articles/PMC2777185/bin/supp_106_48_20411__index.html" data-ga-action="click_feat_suppl">Click here to view.</a></div>
            
         </div></div><div id="ack-a.k.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.k.btitle" style="text-transform: uppercase;">Acknowledgments.</h2><div class="sec"><p>This work was supported by grants from the Swiss National Foundation (grant 310040&#x02013;103671), the Gottfried and Julia Bangerter Rhyner Stiftung, the Burroughs-Wellcome Fund, the Robert Wood Johnson Foundation, the Melanoma Research Alliance, The Starr Cancer Consortium, and the Novartis Institute for Biomedical Research, grants K08CA115927, P50CA093683, and DP2OD002750.</p></div></div><div id="fn-group-a.k.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.k.atitle" style="text-transform: uppercase;">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.k.a.a"> <p class="p p-first-last">The authors declare no conflict of interest.</p></p><p class="fn sec" id="fn-a.k.a.b"><p class="p p-first-last">This article is a PNAS Direct Submission.</p></p><p class="fn sec" id="fn-a.k.a.c"><p class="p p-first-last">This article contains supporting information online at <a href="http://www.pnas.org/cgi/content/full/0905833106/DCSupplemental" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">www.pnas.org/cgi/content/full/0905833106/DCSupplemental</a>.</p></p></div></div><div id="ref-list-a.k.c" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.k.ctitle" style="text-transform: uppercase;">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="element-citation">Martin GS. Cell signaling and cancer. <span><span class="ref-journal">Cancer Cell. </span>2003;<span class="ref-vol">4</span>:167–174.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14522250" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Cell+signaling+and+cancer&amp;author=GS+Martin&amp;volume=4&amp;publication_year=2003&amp;pages=167-174&amp;pmid=14522250&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="element-citation">Weinstein IB. Cancer. Addiction to oncogenes&#x02014;the Achilles heal of cancer. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">297</span>:63–64.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12098689" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cancer.+Addiction+to+oncogenes&#x02014;the+Achilles+heal+of+cancer&amp;author=IB+Weinstein&amp;volume=297&amp;publication_year=2002&amp;pages=63-64&amp;pmid=12098689&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="element-citation">Davies H, et al. Mutations of the BRAF gene in human cancer. <span><span class="ref-journal">Nature. </span>2002;<span class="ref-vol">417</span>:949–954.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12068308" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Mutations+of+the+BRAF+gene+in+human+cancer&amp;author=H+Davies&amp;volume=417&amp;publication_year=2002&amp;pages=949-954&amp;pmid=12068308&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="element-citation">Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">439</span>:358–362.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3306236/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16273091" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition&amp;author=DB+Solit&amp;volume=439&amp;publication_year=2006&amp;pages=358-362&amp;pmid=16273091&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="element-citation">McDermott U, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2007;<span class="ref-vol">104</span>:19936–19941.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2148401/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18077425" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Identification+of+genotype-correlated+sensitivity+to+selective+kinase+inhibitors+by+using+high-throughput+tumor+cell+line+profiling&amp;author=U+McDermott&amp;volume=104&amp;publication_year=2007&amp;pages=19936-19941&amp;pmid=18077425&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="element-citation">McDermott DF, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:2178–2185.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18445842" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Double-blind+randomized+phase+II+study+of+the+combination+of+sorafenib+and+dacarbazine+in+patients+with+advanced+melanoma:+A+report+from+the+11715+Study+Group&amp;author=DF+McDermott&amp;volume=26&amp;publication_year=2008&amp;pages=2178-2185&amp;pmid=18445842&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="element-citation">Rinehart J, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. <span><span class="ref-journal">J Clin Oncol. </span>2004;<span class="ref-vol">22</span>:4456–4462.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15483017" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Multicenter+phase+II+study+of+the+oral+MEK+inhibitor,+CI-1040,+in+patients+with+advanced+non-small-cell+lung,+breast,+colon,+and+pancreatic+cancer&amp;author=J+Rinehart&amp;volume=22&amp;publication_year=2004&amp;pages=4456-4462&amp;pmid=15483017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="element-citation">Flaherty K, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. <span><span class="ref-journal">ASCO Meeting Abstracts May 20. </span>2009;<span class="ref-vol">2009</span>:9000.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ASCO+Meeting+Abstracts+May+20&amp;title=Phase+I+study+of+PLX4032:+Proof+of+concept+for+V600E+BRAF+mutation+as+a+therapeutic+target+in+human+cancer&amp;author=K+Flaherty&amp;volume=2009&amp;publication_year=2009&amp;pages=9000&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="element-citation">Schwartz GK, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. <span><span class="ref-journal">ASCO Meeting Abstracts May 20. </span>2009;<span class="ref-vol">2009</span>:3513.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ASCO+Meeting+Abstracts+May+20&amp;title=A+phase+I+study+of+XL281,+a+selective+oral+RAF+kinase+inhibitor,+in+patients+(Pts)+with+advanced+solid+tumors&amp;author=GK+Schwartz&amp;volume=2009&amp;publication_year=2009&amp;pages=3513&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="element-citation">Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. <span><span class="ref-journal">Cell. </span>2003;<span class="ref-vol">112</span>:831–843.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12654249" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Mechanisms+of+autoinhibition+and+STI-571/imatinib+resistance+revealed+by+mutagenesis+of+BCR-ABL&amp;author=M+Azam&amp;author=RR+Latek&amp;author=GQ+Daley&amp;volume=112&amp;publication_year=2003&amp;pages=831-843&amp;pmid=12654249&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="element-citation">Bentley DR, et al. Accurate whole human genome sequencing using reversible terminator chemistry. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">456</span>:53–59.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2581791/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18987734" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Accurate+whole+human+genome+sequencing+using+reversible+terminator+chemistry&amp;author=DR+Bentley&amp;volume=456&amp;publication_year=2008&amp;pages=53-59&amp;pmid=18987734&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="element-citation">Davies BR, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. <span><span class="ref-journal">Mol Cancer Ther. </span>2007;<span class="ref-vol">6</span>:2209–2219.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17699718" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=AZD6244+(ARRY-142886),+a+potent+inhibitor+of+mitogen-activated+protein+kinase/extracellular+signal-regulated+kinase+kinase+1/2+kinases:+Mechanism+of+action+in+vivo,+pharmacokinetic/pharmacodynamic+relationship,+and+potential+for+combination+in+preclinical+models&amp;author=BR+Davies&amp;volume=6&amp;publication_year=2007&amp;pages=2209-2219&amp;pmid=17699718&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="element-citation">Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK) <span><span class="ref-journal">Semin Oncol. </span>2003;<span class="ref-vol">30</span>:105–116.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14613031" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Oncol&amp;title=CI-1040+(PD184352),+a+targeted+signal+transduction+inhibitor+of+MEK+(MAPKK)&amp;author=LF+Allen&amp;author=J+Sebolt-Leopold&amp;author=MB+Meyer&amp;volume=30&amp;publication_year=2003&amp;pages=105-116&amp;pmid=14613031&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="element-citation">Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. <span><span class="ref-journal">Mol Cell Biol. </span>2002;<span class="ref-vol">22</span>:7593–7602.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC135683/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12370306" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=Identification+of+a+novel+mitogen-activated+protein+kinase+kinase+activation+domain+recognized+by+the+inhibitor+PD+184352&amp;author=AM+Delaney&amp;author=JA+Printen&amp;author=H+Chen&amp;author=EB+Fauman&amp;author=DT+Dudley&amp;volume=22&amp;publication_year=2002&amp;pages=7593-7602&amp;pmid=12370306&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="element-citation">Fischmann T, et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. <span><span class="ref-journal">Biochemistry. </span>2009;<span class="ref-vol">48</span>:2661–2674.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19161339" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Crystal+structures+of+MEK1+binary+and+ternary+complexes+with+nucleotides+and+inhibitors&amp;author=T+Fischmann&amp;volume=48&amp;publication_year=2009&amp;pages=2661-2674&amp;pmid=19161339&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="element-citation">Rodriguez-Viciana P, Rauen KA. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Methods Enzymol. </span>2008;<span class="ref-vol">438</span>:277–289.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18413255" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Methods+Enzymol&amp;title=Biochemical+characterization+of+novel+germline+BRAF+and+MEK+mutations+in+cardio-facio-cutaneous+syndrome&amp;author=P+Rodriguez-Viciana&amp;author=KA+Rauen&amp;volume=438&amp;publication_year=2008&amp;pages=277-289&amp;pmid=18413255&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="element-citation">Nava C, et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: Genotype-phenotype relationships and overlap with Costello syndrome. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:763–771.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2652823/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17704260" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Genet&amp;title=Cardio-facio-cutaneous+and+Noonan+syndromes+due+to+mutations+in+the+RAS/MAPK+signalling+pathway:+Genotype-phenotype+relationships+and+overlap+with+Costello+syndrome&amp;author=C+Nava&amp;volume=44&amp;publication_year=2007&amp;pages=763-771&amp;pmid=17704260&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="element-citation">Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: Implications for therapy. <span><span class="ref-journal">PLoS ONE. </span>2007;<span class="ref-vol">2</span>:e1279.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2093994/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18060073" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Mutation+analysis+of+BRAF,+MEK1+and+MEK2+in+15+ovarian+cancer+cell+lines:+Implications+for+therapy&amp;author=AL+Estep&amp;author=C+Palmer&amp;author=F+McCormick&amp;author=KA+Rauen&amp;volume=2&amp;publication_year=2007&amp;pages=e1279&amp;pmid=18060073&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="element-citation">Pratilas CA, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2009;<span class="ref-vol">106</span>:4519–4524.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2649208/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19251651" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=(V600E)BRAF+is+associated+with+disabled+feedback+inhibition+of+RAF-MEK+signaling+and+elevated+transcriptional+output+of+the+pathway&amp;author=CA+Pratilas&amp;volume=106&amp;publication_year=2009&amp;pages=4519-4524&amp;pmid=19251651&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="element-citation">Dummer R, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. <span><span class="ref-journal">ASCO Meeting Abstracts May 20. </span>2008;<span class="ref-vol">2008</span>:9033.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ASCO+Meeting+Abstracts+May+20&amp;title=AZD6244+(ARRY-142886)+vs+temozolomide+(TMZ)+in+patients+(pts)+with+advanced+melanoma:+An+open-label,+randomized,+multicenter,+phase+II+study&amp;author=R+Dummer&amp;volume=2008&amp;publication_year=2008&amp;pages=9033&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="element-citation">Tsai J, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2008;<span class="ref-vol">105</span>:3041–3046.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2268581/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18287029" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity&amp;author=J+Tsai&amp;volume=105&amp;publication_year=2008&amp;pages=3041-3046&amp;pmid=18287029&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="element-citation">Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. <span><span class="ref-journal">Science. </span>2001;<span class="ref-vol">293</span>:876–880.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11423618" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Clinical+resistance+to+STI-571+cancer+therapy+caused+by+BCR-ABL+gene+mutation+or+amplification&amp;author=ME+Gorre&amp;volume=293&amp;publication_year=2001&amp;pages=876-880&amp;pmid=11423618&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="element-citation">Heinrich MC, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. <span><span class="ref-journal">J Clin Oncol. </span>2003;<span class="ref-vol">21</span>:4342–4349.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14645423" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&amp;author=MC+Heinrich&amp;volume=21&amp;publication_year=2003&amp;pages=4342-4349&amp;pmid=14645423&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="element-citation">Kobayashi S, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:786–792.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15728811" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&amp;author=S+Kobayashi&amp;volume=352&amp;publication_year=2005&amp;pages=786-792&amp;pmid=15728811&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="element-citation">Talpaz M, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>:2531–2541.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16775234" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Dasatinib+in+imatinib-resistant+Philadelphia+chromosome-positive+leukemias&amp;author=M+Talpaz&amp;volume=354&amp;publication_year=2006&amp;pages=2531-2541&amp;pmid=16775234&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">26. <span class="element-citation">Kantarjian H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>:2542–2551.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16775235" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Nilotinib+in+imatinib-resistant+CML+and+Philadelphia+chromosome-positive+ALL&amp;author=H+Kantarjian&amp;volume=354&amp;publication_year=2006&amp;pages=2542-2551&amp;pmid=16775235&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">27. <span class="element-citation">Ohren JF, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2004;<span class="ref-vol">11</span>:1192–1197.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15543157" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Struct+Mol+Biol&amp;title=Structures+of+human+MAP+kinase+kinase+1+(MEK1)+and+MEK2+describe+novel+noncompetitive+kinase+inhibition&amp;author=JF+Ohren&amp;volume=11&amp;publication_year=2004&amp;pages=1192-1197&amp;pmid=15543157&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">28. <span class="element-citation">Dentici ML, et al. Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:733–740.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2947095/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19156172" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Hum+Genet&amp;title=Spectrum+of+MEK1+and+MEK2+gene+mutations+in+cardio-facio-cutaneous+syndrome+and+genotype-phenotype+correlations&amp;author=ML+Dentici&amp;volume=17&amp;publication_year=2009&amp;pages=733-740&amp;pmid=19156172&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">29. <span class="element-citation">Lin WM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:664–673.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10493008/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18245465" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Modeling+genomic+diversity+and+tumor+dependency+in+malignant+melanoma&amp;author=WM+Lin&amp;volume=68&amp;publication_year=2008&amp;pages=664-673&amp;pmid=18245465&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">30. <span class="element-citation">Haigis KM, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>:600–608.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2410301/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18372904" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Differential+effects+of+oncogenic+K-Ras+and+N-Ras+on+proliferation,+differentiation+and+tumor+progression+in+the+colon&amp;author=KM+Haigis&amp;volume=40&amp;publication_year=2008&amp;pages=600-608&amp;pmid=18372904&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31">31. <span class="element-citation">Thomas RK, et al. High-throughput oncogene mutation profiling in human cancer. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:347–351.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17293865" ref="reftype=pubmed&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=High-throughput+oncogene+mutation+profiling+in+human+cancer&amp;author=RK+Thomas&amp;volume=39&amp;publication_year=2007&amp;pages=347-351&amp;pmid=17293865&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=2777185&amp;issue-id=183199&amp;journal-id=2&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Proceedings of the National Academy of Sciences of the United States of America</span> are provided here courtesy of <strong>National Academy of Sciences</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pubreader-link other_item"><a href="/pmc/articles/PMC2777185/?report=reader" class="sidefm-pmclink">PubReader</a></li>
<li class="pdf-link other_item"><a href="/pmc/articles/PMC2777185/pdf/zpq20411.pdf" class="int-view">PDF (1.7M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/2777185/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/2777185/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<div class="collections-button-container" data-article-id="2777185" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="e92dUddu9W4bOSkj1LhC28QD4WY6SARvLdabUv1vREX5dP3fKKoNajCPpHVgy7Hq">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F&amp;text=MEK1%20mutations%20confer%20resistance%20to%20MEK%20and%20B-RAF%20inhibition" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2777185%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777185/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/19915144/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/19915144/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC2777185/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/2777185/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.54110350c77632754ed7.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.586993420cfd.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.bf4d0b9d90eb88f67344.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC2777185/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
